The advent of artificial intelligence and machine learning already promises to shave months to years off of the typical drug discovery timeline—but why stop there? Entos believes it can make the process even faster while using fewer data resources, and it’s raised $53 million to help catapult its efforts.
Other articles
January 14, 2026
Five Berkeley Spinouts Reflect Our Simple Thesis: Back Insatiably Curious Scientists Tackling Massive Problems
At Freeflow Ventures, our investment thesis is straightforward: we back…



